ASCO 2022 Conference Intelligence around HER2 Negative Breast Cancer assets

Case Study of an asset for the HER2 Negative Breast Cancer: ASCO 2022
Scope & Objective:

A large Pharmaceutical company, headquartered in the US, wanted DelveInsight to support them by providing a detailed conference coverage of the oncology drug for the indication HER2 negative breast cancer published during ASCO 2022, including the product description, research and developmental activities, product milestones, future plans, and KOL insights.

Congress Coverage Support:
  • DelveInsight supported the client by creating a focused conference coverage plan in order to gain an in-depth assessment of the drug along with a detailed understanding of the product's developmental activities and key milestones
  • In addition to this DelveInsight also conducted primary research in order to cater to the KOL and Stakeholder insights around the drug
  • High-priority sessions were selected for more focused live coverage
Congress Plan:
  • The team extracted and classified sessions by priorities
  • Captured detailed presentations and understand the business insights
  • KITs and KIQs were aligned with the client’s strategic needs
  • The deliverables enabled the customer to proactive response to competitor activities at ASCO 2022
  • Senior internal stakeholders were timely informed of the latest business updates

Related Insights

In-Licensing Opportunity
In-Licensing Opportunity

A large client based in USA, involved in drug delivery devices, with effective marketing and commercialization presence across the globe, wanted to in-license potential dMTS based drug delivery asset... [...]

View Case
Out Licensing Opportunity
Out-Licensing Opportunity

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from acr... [...]

View Case
Go-To-Market Strategy
Go-To-Market Strategy

A medium pharmaceutical client based in United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe... [...]

View Case

Fill the form to download the case study

I consent to DelveInsight gathering details provided via this form. Check our Privacy Policy to know more.